MRI dye may shield cancer patients from nerve pain
NCT ID NCT00727922
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether mangafodipir, an MRI contrast agent with antioxidant properties, could reduce nerve damage caused by oxaliplatin chemotherapy. Researchers enrolled 23 cancer patients who already had moderate nerve problems from oxaliplatin but needed to continue treatment. The goal was to see if mangafodipir could ease neuropathy and allow more chemotherapy cycles.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cochin
Paris, 75014, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Could sitting up make radiation therapy more comfortable?
- Can we predict dangerous side effects when combining radiation and immunotherapy?
- Family history as a shield: can culturally tailored guidance cut cancer risk?
- A simple screening program could transform cancer aftercare
- Can simple positive activities boost Well-Being in cancer care?